MAZE Maze Therapeutics, Inc.
Price Chart
Executive Summary
Maze Therapeutics reported Q1 2026 net loss of $24.2M ($0.45/share), missing consensus of $0.43/share by 4.7%, with license revenue of $20M from a Shionogi milestone. Positive Phase 2 HORIZON data for MZE829 in AMKD and a strong cash runway into 2029 offset the miss, but the recent $150M offering adds dilution.
Actionable Insight
Watch for additional HORIZON data in late 2026/early 2027 and Phase 2 trial initiations for MZE782 in PKU and CKD, which could be catalysts. The recent dilution and cash burn rate warrant caution despite strong cash runway.
Key Facts
- Q1 2026 net loss $24.2M ($0.45/share) vs consensus ($0.43)
- License revenue $20.0M from Shionogi milestone (no year-ago revenue)
- Cash, equivalents and marketable securities $362.9M at March 31, 2026
- Positive Phase 2 HORIZON data for MZE829: 35.6% mean uACR reduction in broad AMKD
- April 2026 registered offering raised ~$150M gross proceeds
- Cash runway extended into 2029 including April proceeds and $20M milestone
Financial Impact
Q1 2026 net loss $24.2M ($0.45/share), license revenue $20.0M; cash $362.9M; additional $150M offering and $20M milestone in April 2026
Risk Factors
- Dilution from $150M registered offering completed in April 2026
- Clinical trial risks for MZE829 and MZE782
- No approved products; revenue dependent on milestones and partnerships
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293352 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
6d ago
|
Insider Cluster
| $25.40 $24.27 | ▲ +4.45% | ▲ +1.85% | $23.93 (+5.79%) |
|
May 22, 2026
18d ago
|
8-K
| $26.35 $26.05 | ▼ −1.14% | ▼ −1.15% | $23.93 (−9.18%) |
|
May 18, 2026
22d ago
|
Insider Cluster
| $24.46 $25.03 | ▲ +2.33% | ▲ +1.29% | $23.93 (−2.17%) |
|
May 12, 2026
28d ago
|
8-K
| $26.96 $26.96 | · 0.00% | ▲ +0.00% | $23.93 (−11.24%) |
|
May 12, 2026
28d ago
|
Press Release
| $26.96 $26.96 | · 0.00% | ▲ +0.00% | $23.93 (−11.24%) |
|
Apr 22, 2026
6w ago
|
424B5
| $26.01 $25.81 | ▼ −0.77% | ▼ −1.55% | $23.93 (−8.00%) |
|
Mar 25, 2026
10w ago
|
Press Release
| $31.73 $31.71 | ▼ −0.06% | ▲ +1.71% | $23.93 (−24.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access